Ometto Giovanni

Visual Field Outcomes from the Multicenter, Randomized Controlled Laser in Glaucoma and Ocular Hypertension Trial (LiGHT).

A slightly larger proportion of ocular hypertensive and glaucoma patients treated first with medical therapy underwent rapid VF progression compared with those treated first with SLT.

Efficacy of Repeat Selective Laser Trabeculoplasty in Medication-Naive Open-Angle Glaucoma and Ocular Hypertension during the LiGHT Trial.

These exploratory analyses demonstrate that repeat SLT can maintain IOP at or below target IOP in medication-naive OAG and OHT eyes requiring retreatment with at least an equivalent duration of effect to initial laser.

Five-Year Visual Field Outcomes of the HORIZON Trial.

CS-HMS has a significant effect on VF preservation in glaucoma patients compared with CS alone, reducing the proportion of fast progressors.

Hierarchical Censored Bayesian Analysis of Visual Field Progression.

Bayesian hierarchical models improved the detection of VF progression. Accounting for censoring improves the precision of the estimates, but minimal effect is provided by accounting for heteroskedasticity.

Revisiting the Drasdo Model: Implications for Structure-Function Analysis of the Macular Region.

The Drasdo model can effectively account for AL assuming geometric scaling. Method 2 should be used for structure-function analyses.

Two-Year Visual Field Outcomes of the Treatment of Advanced Glaucoma Study (TAGS).

There was no significant difference in the average RoP at 2 years.

Estimating the Distribution of True Rates of Visual Field Progression in Glaucoma.

The distribution of "true" RoPs can be estimated with an exGaussian-LMM, improving model accuracy.

Validating Trend-Based End Points for Neuroprotection Trials in Glaucoma.

The trend-based methods can efficiently detect treatment effects defined by long-term FDA-compatible progression.

Relationship Between Intraocular Pressure and the True Rate of Functional and Structural Progression in the United Kingdom Glaucoma Treatment Study.

VF appeared to deteriorate at a faster rate than structural measurements. However, this could be explained by the floor-effect from nonfunctional tissue. IOP induced a similar acceleration in RoP per mm Hg increase.

Does the Visual Field Improve After Initiation of Intraocular Pressure Lowering in the United Kingdom Glaucoma Treatment Study?

Initial short-term VF changes in the treatment and placebo arms of UKGTS were the same.

Spatial Summation in the Glaucomatous Macula: A Link With Retinal Ganglion Cell Damage.

Macular sensitivity loss in glaucoma is better described by a model in which RA changes with RGC loss. Structural measurements have limited dynamic range.

Improving the Accuracy and Speed of Visual Field Testing in Glaucoma With Structural Information and Deep Learning.

DL structure-function predictions from clinically available OCT scans can improve perimetry in glaucoma patients.

Six-Year Rate of Visual Field Progression in the Laser in Glaucoma and Ocular Hypertension Trial.

First-line SLT was more effective than drops at preserving VF.

A Practical Framework for the Integration of Structural Data Into Perimetric Examinations.

Structurally enhanced perimetric examination can significantly improve test time in healthy subjects and can be delivered through a user-friendly interface. Further testing will need to assess feasibility and performance of S-ZEST in patients with glaucoma.

Comparing the Rate of Retinal Nerve Fiber Layer and Visual Field Loss as Outcomes in Glaucoma Trials.

Using realistic modeling of structure-function progression and test-retest data, MD progression showed higher statistical power cpRFNL as an outcome measure for clinical trials.

Association of Systemic Calcium Channel Blocker Use with Visual Field Progression in a Large Real-World Cohort from Glaucoma Clinics.

Calcium channel blocker use was statistically significantly associated with a slower rate of VF deterioration after multivariable adjustment.

Author Response: The Distribution of True Visual Field Progression Rates in Glaucoma.